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Purpose: To examine whether cardiac chemical exchange saturation 
transfer (CEST) imaging can be serially and noninvasively 
used to probe cell survival or rejection after intramyocar-
dial implantation in mice.
Materials and 
Methods:
Experiments were compliant with the National Institutes 
of Health Guidelines on the Use of Laboratory Animals 
and approved by the Institutional Animal Care and Use 
Committee. One million C2C12 cells labeled with either 
europium (Eu) 10-(2-hydroxypropyl)-1,4,7-tetraazacy-
clododecane-1,4,7-triacetic acid (HP-DO3A) or saline via 
the hypotonic swelling technique were implanted into the 
anterior-lateral left ventricular wall in C57BL/6J (alloge-
neic model, n = 17) and C3H (syngeneic model, n = 13) 
mice. Imaging (frequency offsets of 615 parts per million) 
was performed 1, 10, and 20 days after implantation, with 
the asymmetrical magnetization transfer ratio (MTRasym) 
calculated from image pairs. Histologic examination was 
performed at the conclusion of imaging. Changes in MTRasym 
over time and between mice were assessed by using two-
way repeated-measures analysis of variance.
Results: MTRasym was significantly higher in C3H and C57BL/6J 
mice in grafts of Eu-HP-DO3A–labeled cells (40.2% 6 5.0 
vs 37.8% 6 7.0, respectively) compared with surrounding 
tissue (20.67% 6 1.7 vs 21.8% 6 5.3, respectively; P , 
.001) and saline-labeled grafts (20.4% 6 6.0 vs 21.2% 6 
3.6, respectively; P , .001) at day 1. In C3H mice, MTRasym 
remained increased (31.3% 6 9.2 on day 10, 28.7% 6 
5.2 on day 20; P , .001 vs septum) in areas of in Eu-HP-
DO3A–labeled cell grafts. In C57BL/6J mice, correspond-
ing MTRasym values (11.3% 6 8.1 on day 10, 5.1% 6 9.4 
on day 20; P , .001 vs day 1) were similar to surrounding 
myocardium by day 20 (P = .409). Histologic findings con-
firmed cell rejection in C57BL/6J mice. Estimation of graft 
area was similar with cardiac CEST imaging and histologic 
examination (R2 = 0.89).
Conclusion: Cardiac CEST imaging can be used to image cell survival 
and rejection in preclinical models of cell therapy.
q RSNA, 2016
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demonstrate cell survival or rejection 
after intramyocardial implantation in 
mice.
Materials and Methods
Cell Culture and Labeling
Immortalized mouse skeletal myoblasts 
(C2C12) were labeled with either euro-
pium (Eu) 10-(2-hydroxypropyl)-1,4,7-
tetraazacyclododecane-1,4,7-triacetic 
acid (HP-DO3A, provided by Dr Silvio 
Aime at the University of Turin, Turin, 
Italy) or saline by using a hypotonic 
swelling technique (23). For control ex-
periments, cells were exposed to hypo-
tonic solution with saline substituted for 
Eu-HP-DO3A solution. Full details of cell 
culture and labeling can be found in 
Appendix E1 (online).
Cell Transplantation
Experiments were performed accord-
ing to the National Institutes of Health 
Guidelines on the Use of Laboratory 
Animals and were approved by the In-
stitutional Animal Care and Use Com-
mittee. Cardiac implantation of cells 
involved the use of the “pop-out” tech-
nique (24). Mice were anesthetized and 
maintained with 2% isoflurane in oxygen, 
the pectoral muscles were dissected at 
the fourth intercostal space, mosquito 
oxide nanoparticle–labeled cells (4–7) 
has raised concerns of altered gene 
expression, tissue retention of parti-
cles after cell death, and difficulty in 
differentiating between labeled cells and 
tissue necrosis (2,8–13).
Chemical exchange saturation trans-
fer (CEST) MR imaging is an emerging 
molecular imaging technique wherein 
the contrast (change in signal intensity) 
of either paramagnetic CEST agents 
(14,15) or CEST-active reporter genes 
(16–18) is selectively activated by us-
ing radiofrequency irradiation at target 
specific offset frequencies (19). Subse-
quently, paramagnetic CEST–labeled 
cells or CEST MR imaging reporter 
gene–expressing cells can be visual-
ized without disruption of underlying 
MR image integrity. Prior CEST MR 
imaging studies have been conducted 
to track paramagnetic CEST–labeled 
cells in subcutaneous tumor models in 
mice (14,15) and image CEST reporter 
gene–expressing cells implanted in the 
rodent brain (16–18). While CEST 
MR imaging is suited for cell tracking 
in cardiac cell therapy, conventional 
CEST approaches are unsuitable for 
preclinical cardiac imaging and have 
been limited to stationary organs and 
the lungs (20). Recently, we designed 
a CEST MR imaging method specifi-
cally for preclinical cardiac imaging, 
termed cardiac CEST imaging (21,22) 
and demonstrated the ability to visu-
alize paramagnetic CEST–labeled cells 
24 hours after intramyocardial implan-
tation (22).
In this study, we used two mouse 
models of cardiac cell therapy: one syn-
geneic model in which implanted cells 
derived from the same genetic strain of 
mice survive and proliferate over time 
(C3H genetic background) and one al-
logeneic model in which identical cells 
implanted into mice on a different ge-
netic background (C57BL/6J) undergo 
complete rejection after implantation. 
We hypothesized that CEST contrast 
generated by paramagnetic CEST–la-
beled cells is preserved in surviving cell 
grafts and eliminated in instances of cell 
rejection. The purpose of this study was 
to examine whether cardiac CEST can 
serially and noninvasively be used to 
Published online before print
10.1148/radiol.2016152766 Content codes:  
Radiology 2017; 282:131–138
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Advances in Knowledge
 n Cardiac chemical exchange satu-
ration transfer (CEST) MR im-
aging can be used to serially 
image the fate of implanted cells 
in preclinical models of cell 
therapy.
 n CEST contrast (change in signal 
intensity), measured as the 
asymmetrical magnetization 
transfer ratio, is preserved in 
surviving paramagnetic CEST-
labeled cells for 20 days after 
cardiac implantation in C3H mice 
(28.75 6 5.2 for cell graft vs 
1.4% 6 5.6 for septum, P , 
.001).
 n CEST contrast is eliminated in 
rejected paramagnetic CEST-
labeled cells within 20 days after 
implantation in C57BL/6J mice 
(5.1% 6 9.4 for cell graft vs 
1.1% 6 4.5 for septum, P = .41).
 n Measurement of CEST contrast 
can be used to differentiate sur-
viving cells from those under-
going rejection as early as 10 
days after implantation (31.3% 6 
9.2 for surviving cells vs 11.3% 
6 8.1 for cell rejection, P , 
.001).
 n Assessment of graft size at car-
diac CEST MR imaging demon-
strates a positive association with 
graft size according to histologic 
findings (R2 = 0.89, covariance = 
17%).
Over a decade of investigation into cardiac regeneration with cell therapy has demonstrated limited 
regenerative capacity due to low sur-
vival of injected cells (1). The inability 
to track in vivo cell fate, including sur-
vival or rejection without using ex vivo 
tissue staining, remains an obstacle to 
further progress, including the devel-
opment of methods to enhance cell 
survival (2). Magnetic resonance (MR) 
imaging is used for in vivo imaging of 
infarct healing through characteriza-
tion of cardiac structure, function, per-
fusion, and fibrosis (3). MR imaging 
cell tracking in cell therapy with iron 
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Natick, Mass) by using custom-built 
software. For each mouse and time 
point, one section was selected from 
acquired data to ensure consistent 
section position across time points. 
The end-diastolic image acquired af-
ter saturation at 15 ppm was regis-
tered to the corresponding image ac-
quired after saturation at 215 ppm. 
Maps of the asymmetrical magneti-
zation transfer ratio (MTRasym) were 
then calculated on a voxelwise basis as 
MTRasym = [(S-15 ppm – S15 ppm)/S-15 ppm] 
· 100. Maps of MTRasym are processed 
such that only voxels from the left ven-
tricle are superimposed on correspond-
ing magnitude reconstructed images. 
On the basis of our previous findings, 
regions of interest that encompassed 
the cell graft were defined on day 1 
by using a threshold MTRasym value of 
up to 15% for mice that received Eu-
HP-DO3A–labeled cells (22). At subse-
quent time points, the same regions of 
interest were applied by using anatomic 
details, such as papillary muscles and 
polar distance from right ventricular 
insertion points, to guide placement. 
For mice that received saline-labeled 
cells, a region of interest was de-
fined retrospectively on the appropri-
ate section on the basis of histologic 
identification of the cell graft for C3H 
mice and the identification of the in-
jection site for C57BL/6J mice. Fi-
nally, in all mice, an internal control 
measurement was obtained in the in-
terventricular septum on the section 
that contained injected cells.
Estimation of Graft Size
Cardiac CEST measurement of graft 
size was performed on data acquired 
20 days after implantation of Eu-HP-
DO3A–labeled cells. On the basis 
of our prior findings of appropriate 
threshold values for identifying cell 
grafts, an MTRasym threshold of up to 
15% was used to calculate graft size as 
a percentage of total myocardial area 
(22). Corresponding measures from he-
matoxylin-eosin–stained tissue sections 
were calculated by manually contouring 
blue-stained graft tissue and were ex-
pressed as a percentage of total myo-
cardial area.
Biospin MR Imaging, Ettlingen, Germa-
ny) by using a cylindrical volume coil for 
excitation (outer diameter, 11.2 cm; in-
ner diameter, 8.6 cm) and a four-channel 
phased-array surface coil for detection. 
Anesthesia involved the use of 1.5% iso-
flurane in oxygen, and body temperature 
was maintained (at 37°C) by using cir-
culating water. Electrocardiographic and 
respiratory gating was performed with 
a Small Animal Instruments system 
(SAI, Stonybrook, NY). The site of 
cell injection was identified 1 day af-
ter implantation as areas of disrupted 
pericardium on long-axis images. For 
subsequent imaging, the same section 
location was identified by using the 
distance from the left ventricular apex 
and anatomic features, including pap-
illary muscles. To further ensure that 
data were repeatedly acquired in the 
same section location, pairs of car-
diac CEST images were acquired in 
two to three sections around the ini-
tial site. Briefly, the cardiac CEST pulse 
sequence uses a constant repetition 
time gradient-echo readout to drive ini-
tial CEST weighting into the steady-state 
longitudinal magnetization of the myo-
cardium (22). The acquisition of cine 
images is electrocardiographically and 
respiratory gated, with dummy exci-
tation pulses maintaining steady-state 
conditions. This strategy enables re-
liable CEST imaging of the rapidly beat-
ing mouse heart in the presence of free 
breathing. Imaging parameters included 
field of view, 2.56 3 2.56 cm; matrix, 
256 3 128; true in-plane resolution, 200 3 
100 mm; section thickness, 1 mm; rep-
etition time (msec)/echo time (msec), 
6.92/3.42; four signals acquired; and 
15° flip angle. For CEST saturation, a 
train of spatially nonselective Gaussian 
pulses (8.8 msec; 200-Hz bandwidth; 
1-msec interpulse delay; number of puls-
es, 196; flip angle, 720°; and mean in-
duced transverse magnetic field, or B1, 
14 mT) was applied at offset frequencies 
of 615 parts per million (ppm). The to-
tal acquisition time was 2.5–3.0 minutes 
per cine image or 5–6 minutes per pair.
Data Analysis
Data analysis was performed in Mat-
lab version R2012b (The MathWorks, 
clamps were used to open the pleural 
membrane, and the heart was pressed 
toward the surface while maintaining 
pressure on the thorax. Approximately 
106 cells in 10 mL were injected into the 
anterior-lateral left ventricular midwall by 
using a 27-gauge needle. Afterward, the 
heart was returned to the intrathoracic 
space, followed by evacuation of air and 
incision closure to prevent pneumotho-
rax. The mice were removed from anes-
thesia and allowed to recover in room air.
Mouse Models
A total of 17 male C57BL/6J mice and 
13 C3H mice (The Jackson Laboratory, 
Bar Harbor, Maine) were used. Mice 
from both genetic strains underwent 
transplantation of either cells labeled 
with Eu-HP-DO3A or saline-labeled 
control cells (Table). Imaging was per-
formed 1 week before cell transplantation 
and 1, 10, and 20 days after cell trans-
plantation, after which hearts were ex-
cised, sectioned, and stained by using 
hematoxylin-eosin. Separately, the cel-
lular fraction of murine macrophages 
was quantified from tissue sections 
from C3H (n = 2) and C57BL/6J (n = 2) 
mice that received Eu-HP-DO3A–labeled 
cells via immunostaining (Appendix 
E1 [online]) with a rat antimouse F4/80 
antibody (clone BM8, catalog no. 14–
4801–85; eBioscience, San Diego, Calif). 
C2C12 cells are derived from C3H mice 
(syngeneic model) and will survive and 
proliferate after implantation in C3H 
mice but undergo rejection (allogeneic 
model) in C57BL/6J mice.
Imaging
Imaging was performed with a 7-T hor-
izontal imaging unit (ClinScan; Bruker 
Sample Sizes for Four Experimental 
Cohorts Used in the Study
Cell Type
C3H  
(n = 13)
C57BL/6J  
(n = 17)
Eu-HP-DO3A– 
labeled cells
n = 6 n = 8
Saline-labeled  
control cells
n = 7 n = 9
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of Eu-HP-DO3A eliminated the previ-
ously observed CEST contrast in areas 
of implanted cells within 20 days and 
was confirmed at histologic examination 
(Fig E2 [online]). In both C3H and 
C57BL/6J mice, the implantation of 
saline-labeled (control) C2C12 cells did 
not result in any change in CEST con-
trast in areas of either surviving cells or 
rejected cells (Fig E3 [online]).
Repeated measurement of MTRasym 
in areas of implanted cells and inter-
nal septal control regions demonstrated 
Representative MTRasym maps acquired 
1 and 20 days after implantation and 
corresponding histologic images (Fig 1) 
demonstrate the capacity to identify 
surviving Eu-HP-DO3A–labeled cells on 
the basis of increased CEST contrast at 
15 ppm. Identical imaging of C57BL/6J 
mice, in which implanted cells under-
went rejection, demonstrated increased 
MTRasym values in the area of implanted 
Eu-HP-DO3A–labeled cells 24 hours 
after implantation (Fig 2). However, 
rejection of labeled cells and clearance 
Statistics
Statistical analysis was performed with 
SigmaPlot version 13 software (Systat 
Software, San Jose, Calif). Compar-
ison of MTRasym values between Eu-
HP-DO3A–labeled cell grafts, sep-
tal regions, and saline-labeled cell 
grafts and values over time was per-
formed by using two-way repeated-
measures analysis of variance, with 
pairwise comparisons made by using 
the Holm-Sidak method, which was also 
used for comparison of MTRasym values 
over time in Eu-HP-DO3A–labeled cell 
grafts between C3H and C57BL/6J mice. 
The Student t test was used to com-
pare MTRasym measurements prior to 
cell implantation and to compare quan-
tification of graft size according to his-
tologic findings. The association of graft 
size between MR imaging and histo-
logic findings was examined by using 
Bland-Altman analysis. A Shapiro-Wilk 
test was used to confirm the normal 
distribution of all data. A P value of less 
than .05 was used to indicate a signifi-
cant difference.
Results
CEST imaging of the heart with the pa-
rameters selected for this study yielded 
a mean signal-to-noise ratio 6 standard 
deviation of 19.8 arbitrary units (a.u.) 6 
4.1 and contrast-to-noise ratios of 7.3 
a.u. 6 2.9 and 7.3 a.u. 6 5.6 between 
myocardium and blood or lung, re-
spectively. The mean MTRasym values 
measured in the anterior-lateral wall 
(20.3% 6 1.9 for C3H vs 21.5% 6 1.1 
for C57BL/6J, P = .608) and in the sep-
tum (1.8% 6 2.2 for C3H vs 0.6% 6 
1.1 for C57BL/6J, P = .595) prior to cell 
transplantation were similar in C3H 
(n = 7) and C57BL/6J (n = 5) mice (rep-
resentative images are shown in Fig E1 
[online]). The mean heart rates during 
the study time course were 499 beats 
per minute 6 76 and 513 beats per mi-
nute 6 63 for C3H and C57BL/6J mice, 
respectively. Repeated imaging of C3H 
mice in which implanted C2C12 cells 
survived demonstrated significantly 
increased MTRasym values in grafts 
of Eu-HP-DO3A–labeled cells com-
pared with surrounding myocardium. 
Figure 1
Figure 1: (a, b) Longitudinal cardiac CEST images of the survival of Eu-HP-DO3A–labeled cells in C3H 
mice. Twenty-four hours after implantation (a), significantly increased MTR
asym
 values were observed adjacent 
to the inferior papillary muscle (arrow), corresponding to the location of Eu-HP-DO3A–labeled cells. After 
20 days (b), increased MTR
asym
 was still observed in the same myocardial region surrounding the inferior 
papillary muscle (arrow). The proliferation of labeled cells and the likely dilution of Eu-HP-DO3A with cell 
division reduced the MTR
asym
 values of the graft relative to day 1. (c) Photomicrograph (hematoxylin-eosin 
stain; original magnification, 34) of the corresponding histologic slice demonstrates a graft of proliferating 
cells (blue) adjacent to the inferior papillary muscle in a similar location to increased MTR
asym
 values seen on 
b. (d) Higher magnification photomicrograph (hematoxylin-eosin stain; original magnification, 320) of the 
area on c enclosed within the black box demonstrates the presence of proliferating cells (arrows) near the 
endocardial surface at the boundary of the papillary muscle.
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declined gradually after implantation 
and were significantly reduced by 
20 days after implantation compared 
with initial measurements (Fig 3). In 
C57BL/6J mice, CEST contrast was 
significantly increased within grafts of 
Eu-HP-DO3A–labeled cells 1 day after 
implantation when compared with sep-
tal regions of interest and saline-labeled 
cell grafts (Fig 3). However, MTRasym 
values within regions of labeled cell 
grafts decreased significantly within 10 
days of implantation. By 20 days after 
implantation, MTRasym values were in-
distinguishable from either surrounding 
myocardium (P = .409) or saline-la-
beled control animals (P = .254). MTRa-
sym values within Eu-HP-DO3A–labeled 
cell grafts were statistically similar (P = 
.564) in C3H and C57BL/6J mice 1 day 
after implantation but were significantly 
(P , .001) lower in C57BL/6J mice 10 
and 20 days after implantation (Fig 3).
The survival or rejection of C2C12 
cell grafts was confirmed by hematoxylin- 
eosin staining and assessed as the per-
centage of total left ventricular myocar-
dial area. In C3H mice, surviving C2C12 
cells resulted in similar graft sizes in 
Eu-HP-DO3A and saline-labeled cell 
grafts (12.0% 6 3.3 for Eu-HP-DO3A 
vs 12.9% 6 9.3 for saline, P = .825). 
The rejection of C2C12 cell grafts in 
C57BL/6J mice was similar for both Eu-
HP-DO3A and saline-labeled cells (1.0% 
6 1.0 for Eu-HP-DO3A vs 0.7% 6 
0.5 for unlabeled cells, P = .409). As-
sessment of Eu-HP-DO3A–labeled graft 
size was similar between cardiac CEST 
imaging and histologic examination for 
most grafts but was underestimated by 
using MR imaging for grafts larger than 
12% of ventricular mass (Fig 4). The 
coefficient of variation in calculation of 
graft size was 17%. Staining of isolated 
tissue sections for murine macrophages 
(Fig 5) demonstrated that F4/80-posi-
tive macrophages accounted for 1.2% 6 
0.3 and 0.9% 6 0.1 of the cells in the 
graft regions for C3H and C57BL/6J 
mice, respectively.
Discussion
The results of this study demonstrate 
the application of cardiac CEST MR 
comparison to internal control re-
gions of interest in the septum and 
in comparison to regions of inter-
est that contained implanted saline-
labeled cells in genetically identical 
mice (Fig 3). Within regions of Eu-HP-
DO3A–labeled cells, MTRasym values 
different patterns for surviving cells 
when compared with cells undergoing 
rejection (Fig 3). In C3H mice, the CEST 
contrast in tissue regions containing 
Eu-HP-DO3A–labeled cells remained 
significantly increased throughout 
the time course of examination in 
Figure 2
Figure 2: Cardiac CEST images show how the rejection of implanted Eu-HP-DO3A–labeled cells in 
C57BL/6J mice leads to elimination of initial CEST contrast. (a) Implantation of Eu-HP-DO3A–labeled cells 
in a representative C57BL/6J mouse resulted in increased MTR
asym
 values in the lateral ventricular wall in 
close proximity to the inferior papillary muscle 24 hours after implantation (arrow), similar to that observed in 
C3H mice. (b) However, at 20 days after implantation, MTR
asym
 values in the same myocardial region (arrow) 
decreased and were indistinguishable from surrounding myocardium.
Figure 3
Figure 3: Bar graphs illustrate the measurement of MTR
asym
, which allows differentiation of (a) cell survival 
from (b) cell rejection. In C3H mice (a), MTR
asym
 values in the region that contains Eu-HP-DO3A–labeled cells 
(cell graft) were significantly higher compared with septal regions (septum) in the same hearts and compared 
with corresponding regions after implantation of saline-labeled control cells (saline graft) in genetically iden-
tical mice at all measured time points. By 20 days after implantation, the mean MTR
asym
 values in cell grafts 
were significantly lower when compared with values 1 day after implantation. In C57BL/6J mice (b), MTR
asym
 
values were increased 1 day after implantation in areas of Eu-HP-DO3A–labeled cells when compared with 
septal regions and saline-labeled controls and remained significantly increased 10 days after implantation 
but were similar 20 days after implantation. By 10 days, MTR
asym
 values in the region of implanted Eu-HP-
DO3A–labeled cells were significantly reduced compared with both the initial values 1 day after implantation 
and the corresponding values in C3H mice at identical time points. Bars represent P values less than .05 at 
identical time points. ∗ 5 P , .05 versus day 1 in the same region, † = P , .05 versus cell graft in C3H 
mice at the same time point.
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of C2C12 cells in C3H mice by 20 days 
after implantation. Importantly, label-
ing of C2C12 cells with Eu-HP-DO3A 
generated robust CEST contrast at the 
time of implantation that was preserved 
throughout the course of our study and 
did not affect the growth rate of C2C12 
grafts. By 20 days after implantation, 
the moderate reduction in MTRasym values 
in Eu-HP-DO3A–labeled grafts likely 
resulted from dilution of label with cell 
division, which presents a boundary 
condition for the detection of surviving 
cells. In our study, we did not observe 
an eventual loss of CEST contrast; how-
ever, we were unable to perform con-
tinued examination beyond 20 days af-
ter implantation owing to an increase 
in arrhythmias and death caused by the 
growth of C2C12 grafts.
MR imaging tracking of cells after 
cardiac transplantation was previously 
widely explored via iron oxide nanopar-
ticle labeling; however, tissue retention 
of nanoparticles for up to 6 weeks af-
ter the death of labeled cells results 
in inaccurate detection of cell survival 
(2,8–13). In this study, the rejection of 
Eu-HP-DO3A–labeled C2C12 cells in 
C57BL/6J mice resulted in rapid loss 
of CEST contrast. The clearance of 
Eu-HP-DO3A from myocardium after 
intravenous injection was previously 
demonstrated by using dynamic mea-
surement of cardiac MTRasym for 30 
minutes after injection (21). In Eu-HP-
DO3A–labeled cells undergoing rejec-
tion, Eu-HP-DO3A that is released af-
ter cell rupture is likely cleared through 
mechanisms similar to those observed 
previously. However, in this study, we 
did not examine whether removal of 
Eu-HP-DO3A by means of inflamma-
tory mechanisms contributes to MTRasym 
normalization after rejection. Impor-
tantly, given renewed concerns about 
the accumulation of gadolinium in re-
gions of the brain, even in individuals 
with preserved renal function (27,28), 
further studies are necessary to under-
stand clearance of paramagnetic CEST 
agents after cell death.
The implantation of C2C12 cells in 
C3H and C57BL/6J mice models the two 
extreme outcomes of cell therapy: high 
survival with rapid proliferation that 
implantation and complete loss of CEST 
contrast within 20 days. Finally, assess-
ment of graft size by applying a threshold 
MTRasym value was similar to that mea-
sured at histologic examination.
Myocardial implantation of C2C12 
cells is an established cardiac cell ther-
apy model for evaluating MR imaging 
cell-tracking techniques (13,25,26). In 
a prior study, transgenic ferritin heavy-
chain overexpressing C2C12 cells im-
planted into the hearts of C3H mice 
were visualized by using T2*-weighted 
MR imaging 3 weeks after implantation 
(25). We observed similar engraftment 
imaging for serial tracking of cell sur-
vival or rejection after cardiac trans-
plantation. In both models, grafts of 
viable Eu-HP-DO3A–labeled cells were 
clearly distinguishable from surround-
ing myocardium immediately after im-
plantation. The implantation of saline-
labeled cells as controls resulted in no 
changes in MTRasym values, regardless 
of cell fate and time. While tissues that 
contained surviving Eu-HP-DO3A–la-
beled cells demonstrated preserved 
CEST contrast for 20 days, the rejec-
tion of identical cells led to immediate 
reductions in MTRasym by 10 days after 
Figure 4
Figure 4: Plots show the comparison of graft size according to cardiac CEST imaging and histologic 
findings. (a) The quantification of graft size measured as a percentage of left ventricular (LV ) myocardial area 
according to cardiac CEST imaging across all mice in which Eu-HP-DO3A cells were implanted demonstrated 
association with corresponding histologic measurements. (b) Bland-Altman analysis demonstrated close 
agreement in graft size, with slight underestimation of graft size according to MR imaging in grafts larger 
than 12% of left ventricular area.
Figure 5
Figure 5: Photomicrographs show macrophage staining in C3H cardiac tissue. (a) Nuclear staining (496- 
diamidino-2-phenylindole·2HCl, or DAPI; original magnification, 340 composite) of a cross-section of 
cardiac tissue from a mouse that underwent implantation of Eu-HP-DO3A–labeled C2C12 cells. (b) Photomi-
crograph with higher magnification of a region of interest within the cell graft (original magnification, 3400 
composite) is shown after immunostaining for murine macrophages (F4/80, red) and cell nuclei (DAPI, blue). 
Murine macrophages (arrow) were not present in high numbers in C3H cardiac tissue 20 days after cell 
implantation. Corresponding images from a C57BL/6J mouse are found in Figure E4 (online).
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development of continuous wave ap-
proaches by using multichannel parallel 
transmit and receive technology will en-
able substantial reductions in required 
saturation energy. Finally, confining 
CEST imaging and histologic analysis to 
a limited number of sections limited the 
ability to obtain volumetric information 
about graft size. A more thorough vali-
dation of graft size measurement should 
be performed in a future study by com-
paring whole-heart cardiac CEST imag-
ing to whole-heart histologic findings.
In conclusion, cardiac CEST cell 
tracking can serve as a tool for preclin-
ical research of emerging methods to 
enhance the survival of implanted stem 
cells. Since CEST contrast is selectively 
activated, the combined use of CEST-
active biomaterials (33), CEST MR im-
aging reporter genes (16,18,32), and 
multiagent paramagnetic CEST labeling 
of different cell populations (15) has 
the potential to demonstrate multiple 
processes that drive cell fate decisions 
in regenerative therapy.
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